Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co. (NYSE: MRK) is a global pharmaceutical leader with a 350-year legacy of medical innovation. This news hub provides investors and healthcare professionals with direct access to official announcements, financial disclosures, and research developments shaping the company's trajectory.
Track MRK's latest regulatory milestones, clinical trial results, and strategic partnerships through verified press releases and curated analysis. Our repository includes earnings call transcripts, FDA approval updates, and global health initiatives—all organized for efficient research and due diligence.
Key updates on therapeutic advancements in oncology, vaccines, and infectious diseases are maintained alongside financial performance data. Bookmark this page for real-time access to Merck's corporate communications and market-moving developments in the pharmaceutical sector.
Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) announces the enrollment of subjects in a treatment arm evaluating the combination of its breast cancer vaccine with Keytruda (pembrolizumab) by its partner, Cleveland Clinic. The trial aims to determine if the vaccine/Keytruda combination increases immune response against triple negative breast cancer (TNBC), with potential synergistic effects. The company looks forward to the presentation of updated data from this trial at the San Antonio Breast Cancer Symposium in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary
Merck (NYSE: MRK) has received FDA approval for the expanded indication of ERVEBO, a vaccine to prevent Zaire ebolavirus disease in individuals 12 months and older. The vaccine was previously approved for those 18 and older. The European Medicines Agency's Committee also recommended expanded approval for individuals 1 year and older. ERVEBO has a contraindication for individuals with a history of severe allergic reactions to any component of the vaccine. The vaccine's effectiveness when administered with other medications is unknown. Merck has also confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
-
Rhea-AI Summary
Merck reports Q2 2023 financial results with total worldwide sales of $15.0 billion, an increase of 3% from Q2 2022. Key highlights include growth in KEYTRUDA and GARDASIL sales, decline in LAGEVRIO sales, and a GAAP loss per share of $2.35.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
Rhea-AI Summary
Merck (MRK) announces positive Phase 3 study results for KEYTRUDA in combination with chemotherapy for high-risk, early-stage ER-positive, HER2-negative breast cancer, showing a significant improvement in pCR rate compared to neoadjuvant placebo plus chemotherapy. The trial will continue to evaluate the other primary endpoint of event-free survival. Safety profile consistent with previous studies. Results to be presented at upcoming medical meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
-
Rhea-AI Summary
Merck (NYSE: MRK) Announces Positive Phase 3 Results for V116 Pneumococcal Vaccine, Demonstrating Strong Immune Responses in Adults
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary
Merck and Moderna initiate Phase 3 trial for V940 (mRNA-4157) in combination with KEYTRUDA as adjuvant treatment for melanoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
Rhea-AI Summary
Merck announces quarterly dividend of $0.73 per share for Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
-
Rhea-AI Summary
Merck & Co., Inc. (MRK) announces multiple awards for their innovative green chemistry solutions, highlighting their commitment to environmental sustainability and responsible operations. The awards include the 2023 Peter J. Dunn Award and the 2022 Green Chemistry Award, recognizing the development of sustainable manufacturing processes and the use of natural substances to reduce hazardous waste. Merck has also received the Green Chemistry Challenge Award for the sixth consecutive year, showcasing their dedication to environmental stewardship and product innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
-
Rhea-AI Summary
Merck (MRK) announced that the CHMP of the EMA has recommended the approval of gefapixant, an oral treatment for adults with refractory or unexplained chronic cough. This recommendation will be reviewed by the EC for marketing authorization in the EU, with a final decision expected later this year. The positive opinion is based on results from the COUGH-1 and COUGH-2 clinical trials, demonstrating a reduction in 24-hour cough frequency in adults treated with gefapixant 45 mg twice daily versus placebo at 12 weeks (COUGH-1) and 24 weeks (COUGH-2).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
Rhea-AI Summary
Merck (MRK) receives positive CHMP opinion for KEYTRUDA in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in the EU. The recommendation is based on positive progression-free survival results from the Phase 3 KEYNOTE-811 trial, showing a statistically significant improvement in PFS and ORR compared to trastuzumab and chemotherapy alone in patients whose tumors expressed PD-L1 (CPS ≥1).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
Merck & Co
Nasdaq:MRK
MRK Rankings
MRK Stock Data
199.22B
2.51B
0.07%
80.45%
1.62%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
KENILWORTH